Newsroom | 4724 results

SAINT AUGUSTINE, Fla.--(BUSINESS WIRE)--Kihealth, a leader in molecular diagnostics, today announced it has won the Innovation of the Year challenge at the American Diabetes Association’s 85th Scientific Session held in Chicago. Kihealth’s pioneering liquid-biopsy test, which measures the rate of pancreatic beta‑cell death, earned top honors among five finalists for its potential to revolutionize early diabetes detection. Dubbed the “Super Bowl of diabetes innovation,” this prestigious award ha...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the presentation of preclinical data on MAR002, a novel growth hormone receptor (GHR) antagonist antibody for the treatment of acromegaly, at the 2025 Annual Meeting of the Endocrine Society (ENDO). The oral presentation, titled “Developmen...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oak Hill Bio, a biotechnology company focused on developing life-changing therapies for people with rare diseases, today announced the publication in Nature Medicine of the results of the rugonersen Phase 1 TANGELO study in 1 to 12 year old children with Angelman syndrome.1 Oak Hill Bio recently obtained exclusive rights to rugonersen and plans to initiate a Phase 3 study in patients with Angelman syndrome in early 2026. The results published today (The UBE3A-...

MANHASSET, N.Y.--(BUSINESS WIRE)--Scientists and engineers at Northwell Health’s Feinstein Institutes for Medical Research conduct bioelectronic medicine research to treat disease and injury, and recently found that focused ultrasound (FUS) has potential to manage high blood sugar after surgery. Published recently in Bioelectronic Medicine, an open-access journal distributed by the Feinstein Institutes and BMC, part of Springer Nature, used FUS to target a bundle of nerves – including branches...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) the leading digital health and wellness platform, today announced its plans to bring its affordable, holistic weight loss program to Canada, timed with the anticipated first-ever availability of generic semaglutide anywhere in the world. This move follows the recent closing of the company's acquisition of ZAVA, the pioneering digital health platform in Europe. Almost two thirds of adults in Canada are overweight or living...

SAN DIEGO--(BUSINESS WIRE)--ClearNote Health has received UK Conformity Assessed marking for its Avantect® Pancreatic Cancer Test....

EL SEGUNDO, Californie--(BUSINESS WIRE)--Mattel, Inc. (NASDAQ : MAT) annonce aujourd'hui que Barbie® lance la première poupée Barbie atteinte de diabète de type 1 (DT1). Cet ajout à la gamme permet à un plus grand nombre d’enfants de se voir reflétés dans Barbie et encourage un jeu qui va au-delà de l’expérience vécue par un enfant, favorisant ainsi un plus grand sentiment d’inclusion et d’empathie, tous des piliers de la mission de la marque Barbie. « L’introduction d’une poupée Barbie atteint...

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Mattel, Inc. (NASDAQ: MAT) announced today that Barbie® is debuting the first Barbie doll with type 1 diabetes (T1D). This addition to the line enables more children to see themselves reflected in Barbie and encourages doll play that extends beyond a child’s own lived experience, thereby fostering a greater sense of inclusion and empathy – all pillars of the Barbie brand’s mission. “Introducing a Barbie doll with type 1 diabetes marks an important step in ou...

SAN DIEGO--(BUSINESS WIRE)--Eluciderm, Inc., a clinical-stage pharmaceutical company developing small molecule therapeutics designed to promote healing and regenerative repair of injured tissue, announced today that on June 30, 2025 the company received clearance from the U.S. Food & Drug Administration (FDA) for its Investigational New Drug (IND), ELU42, for a Phase 1/2a open-label study evaluating safety and efficacy in patients with diabetic foot ulcers (DFUs). ELU42 is a novel, topical,...

MIAMI--(BUSINESS WIRE)--In major diabetes research news just published in Nature Communications, scientists at the Diabetes Research Institute (DRI) at the University of Miami have shown that a small peptide, called THR-123, can trigger regeneration of insulin-producing beta cells in the pancreas, restoring normal blood sugar levels in pre-clinical experimental models. This regenerative effect, achieved without cell transplantation, offers new hope for treating insulin-dependent diabetes throug...